DEF: Cycurion Seeks Shareholder Vote on Warrant Exercise

Cycurion, Inc. calls a special meeting to approve the issuance of up to 3.3 million common shares from a December 2025 private placement to comply with Nasdaq rules.

Summary

• A special meeting of stockholders is scheduled for February 26, 2026, to vote on two proposals.
• The primary proposal seeks approval, as required by Nasdaq Listing Rule 5635(d), for the issuance of up to 3,314,920 shares of common stock upon the exercise of warrants issued in a private placement that closed on December 5, 2025.
• The private placement involved the sale of pre-funded warrants (1,657,460 shares) and warrants (3,314,920 shares) to a single institutional accredited investor, Armistice Capital Master Fund Ltd.
• The warrants have an exercise price of $3.62 per share and will not be exercisable without stockholder approval.
• If approved, the exercise of these warrants could generate up to approximately $12 million in gross proceeds for the company, which are intended for working capital and general corporate purposes.
• The second proposal seeks approval to adjourn the special meeting if necessary to solicit additional proxies.
• As of the record date, January 21, 2026, there were 4,188,187 shares of common stock and 960,224 shares of preferred voting stock outstanding, totaling 5,148,411 voting shares.
• The Board of Directors unanimously recommends voting FOR both the Warrant Exercise Proposal and the Adjournment Proposal.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral to slightly negative. While it seeks approval for a capital infusion, the underlying private placement has already occurred, and the approval is a procedural necessity. The potential for significant dilution and the lower exercise price of the new warrants compared to older ones suggest ongoing capital needs and potentially less favorable financing terms.

Positives

• Approval of the Warrant Exercise Proposal could provide Cycurion with up to approximately $12 million in gross proceeds, assuming all warrants are exercised for cash at the initial exercise price of $3.62 per share.
• These potential funds are intended for working capital and general corporate purposes, which could support operations.

Negatives

• Approval of the Warrant Exercise Proposal will result in future dilution for existing stockholders, as 3,314,920 additional shares of common stock would become outstanding upon full exercise of the warrants.
• The sale of these newly issued shares into the public market could materially and adversely affect the market price of Cycurion's common stock.
• If the Warrant Exercise Proposal is not approved, the company may incur substantial additional costs and expenses from holding multiple special meetings to seek approval, which could adversely impact funding for operations, clinical trials, and product development.

Risks

• Failure to obtain stockholder approval for the Warrant Exercise Proposal means the warrants will not be exercisable, potentially depriving the company of up to $12 million in gross proceeds.
• The company may be required to hold multiple special meetings if the Warrant Exercise Proposal is not approved, incurring additional costs and expenses that could impact operations, clinical trials, and product development.
• The issuance of warrant shares will dilute existing stockholders' ownership interests.
• The sale of warrant shares into the public market could adversely affect the market price of the common stock.
• The exercise price of the warrants is subject to adjustment, including voluntary reductions by the company, which would result in less proceeds.
• The company is subject to various risks identified in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, including maintaining Nasdaq listing, funding operations, achieving profitability, successful acquisitions, attracting talent, and regulatory compliance.

Future Outlook

The company intends to use the net proceeds from the private placement for working capital and general corporate purposes. It acknowledges that failure to approve the Warrant Exercise Proposal could adversely impact its ability to fund operations, advance clinical trials, and develop and commercialize diagnostic tests or therapeutic product candidates. The company also highlights risks related to maintaining its Nasdaq listing, achieving and sustaining profitability, acquiring cybersecurity companies, attracting and retaining talent, and complying with laws and regulations.

Management Comments

• "We look forward to your continued support." L. Kevin Kelly, Chief Executive Officer and Chairman.
• "The Board of Directors believes that if we fail to receive a sufficient number of votes to approve the Warrant Exercise Proposal, it is in the best interests of the stockholders to enable the Board of Directors to continue to seek to obtain a sufficient number of additional votes to approve any or all of the proposals."

Industry Context

StockSavvy.ai notes that this filing reflects a common practice for companies listed on Nasdaq, where shareholder approval is required for significant equity issuances (20% or more of outstanding shares) outside of public offerings. For a cybersecurity consolidator like Cycurion, securing capital is crucial for funding operations, potential acquisitions, and R&D. The reliance on warrant exercises for capital, while providing potential funds, also introduces dilution, a common trade-off in growth-oriented sectors. The company's stated use of proceeds for 'working capital and general corporate purposes' is broad, suggesting ongoing operational needs and strategic flexibility within the competitive cybersecurity landscape.

Comparison to Industry Standards

• The requirement for shareholder approval for equity issuances exceeding 20% of outstanding shares (Nasdaq Listing Rule 5635(d)) is a standard corporate governance practice for companies listed on major U.S. exchanges, ensuring transparency and shareholder oversight for potentially dilutive transactions.
• The exercise price of $3.62 for the warrants, compared to the $11.50 exercise price of older PIPE and Public Warrants, suggests a significant decline in the company's perceived value or a need to offer more attractive terms to secure recent financing, which is not uncommon for companies facing capital constraints or seeking to incentivize warrant exercise in a challenging market.
• The engagement of a proxy advisor like D.F. King & Co., Inc. for a fee of $10,000 plus expenses is a standard practice for companies seeking to maximize shareholder participation and ensure successful proxy solicitations, especially for critical votes like equity issuances.

Corporate Governance

Related Party Transactions

• The private placement involved a single institutional accredited investor, Armistice Capital Master Fund Ltd., which could be considered a significant investor relationship.
• Executive officers and directors entered into lock-up agreements with the Placement Agent in connection with the private placement.
• The company has a pre-funded warrant agreement with Seward & Kissel LLP, where shares are exercisable for approximately $1.3 million in legal fees and expenses, indicating a business relationship with a legal service provider.

Stakeholder Impact

• **Shareholders**: Will experience dilution if the Warrant Exercise Proposal is approved and warrants are exercised. The market price of common stock could be adversely affected by the sale of these shares. Voting is crucial for approving the capital raise and avoiding additional meeting costs.
• **Company Operations**: Potential proceeds from warrant exercise (up to $12 million) are critical for funding working capital and general corporate purposes, impacting the company's ability to fund operations, advance clinical trials, and develop products.
• **Management/Board**: The Board unanimously recommends approval, indicating their belief that the capital is necessary for the company's future. Failure to approve could lead to increased administrative burden and costs for management.
• **Warrant Holders (Armistice Capital Master Fund Ltd.)**: Their ability to exercise warrants and realize value is contingent on stockholder approval.

Next Steps

• Stockholders are urged to vote on the Warrant Exercise Proposal and the Adjournment Proposal at the Special Meeting on February 26, 2026.
• If the Warrant Exercise Proposal is not approved at the first meeting, the company is required to call subsequent meetings every 90 days until approval is obtained or the warrants are no longer outstanding.
• The company intends to announce preliminary voting results at the Special Meeting and publish final results in a Current Report on Form 8-K within four business days.

Key Dates

Recommendation

The filing is primarily a procedural request for shareholder approval of a dilutive financing event that has already occurred. While the potential capital infusion is positive for operations, the significant dilution and the lower exercise price of the new warrants compared to older ones suggest ongoing financial challenges. The unanimous board recommendation for approval indicates the necessity of this capital. Investors should hold to observe the outcome of the vote and the subsequent impact on the company's financial health and stock performance, as the immediate impact is likely priced in given the private placement has closed.

Keywords

Warrant Exercise, Private Placement, Stockholder Approval, Nasdaq Listing Rule 5635(d), Common Stock Dilution, Special Meeting, Corporate Governance, Capital Raise, CYCURION, Proxy Statement